KOSPIBiotech & Pharma000220

Yuyu Pharma

₩3,700▼ 0.13%2026-11-18 close
Market Cap
₩58.3B
Turnover
₩100M
Volume
30K
Shares out.
15.8M
PER
5.5×
PBR
0.5×
EPS
₩667
Dividend Yield
3.12%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩115 per share · Prices as of the 2026-11-18 close

01

Report overview

Yuyu Pharma: Sales Up Three Straight Quarters, Profit Slows

Yuyu Pharma's quarterly sales rose for three straight quarters from the first quarter of 2026 through the third quarter, while operating profit has fallen for two straight quarters since its first-quarter peak, so growth and profit are moving in different directions.

  1. 1

    Sales reached KRW 37 billion in the third quarter of 2026, up 0.8% from the prior quarter but down 2.1% from a year earlier, so the quarterly gains have not yet lifted sales above the year-earlier level.

  2. 2

    Operating profit in the third quarter of 2026 was KRW 3.27 billion, down 34.4% from a year earlier. Full-year 2025 operating profit was KRW 11 billion, down 5.8% from 2024.

  3. 3

    Revenue of KRW 140.9 billion in 2025 was the highest of the 2022–2025 period. Operating results moved from a loss of KRW 592 million in 2022 to an operating profit of KRW 11.7 billion in 2024.

  4. 4

    On November 17, 2026, the company announced provisional standalone operating profit of KRW 13.2 billion for January through September, up 53.1% from a year earlier. Because this is a standalone figure, it is on a different basis from the consolidated quarterly results in the periodic reports.

  5. 5

    In its 2026 corporate value-up plan disclosed on March 24, 2026, the company said it aimed to complete a treasury share cancellation in the first half and work toward a higher dividend.

02

Business structure

Yuyu Pharma is a pharmaceutical company centered on medicines, which it complements with a health functional food unit and a medical device unit.

Of consolidated sales of KRW 35.5 billion in the first quarter of 2026, the pharmaceutical segment contributed KRW 27.2 billion, or 76.4%, while the health functional food segment contributed KRW 7.6 billion and the medical device segment KRW 800 million.

Within pharmaceuticals, the soft capsule product group, which includes the hyperlipidemia treatment Neumaco, is the largest, followed by the coated tablet group, which includes the peripheral circulation improver Tanamin.

In the first quarter of 2026, the coated tablet products generated KRW 10 billion and the soft capsule products KRW 13.03 billion, and the two groups together reached KRW 23.03 billion, or 64.7% of total sales.

Pharmaceutical segment sales in 2025 were KRW 96.7 billion, up 4.1% from the prior year on a standalone basis, and soft capsule sales rose 20.9% to KRW 45.7 billion. The company puts its generic share at roughly 70%, so the revenue base is sensitive to drug pricing policy.

Prescription drugs sold to hospitals and clinics account for close to 80% of sales, which makes sales capability central to the business.

Companion animal products are being pushed as a new growth engine from 2026, and the company plans to use its YUNICAP multi-form capsule platform in its contract manufacturing business. The health functional food unit performs OEM and ODM work.

Among listed Korean pharmaceutical companies, Yuyu Pharma is on the smaller side by sales, which limits its room for R&D spending relative to large pharma peers.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩37.8B₩5B13.2%
2025Q4₩34.3B-₩100M−0.4%
2026Q1₩35.5B₩4.3B12.1%
2026Q2₩36.7B₩4B10.9%
2026Q3₩37B₩3.3B8.8%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩138.9B-₩600M-₩6B−0.4%−5.1%58.2%
2023₩137.2B₩400M-₩7.2B0.3%−6.4%64.7%
2024₩133.1B₩11.7B₩8.7B8.8%7.0%53.8%
2025₩140.9B₩11B₩8.2B7.8%6.3%47.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-18

04

Earnings analysis

In the annual figures from the periodic reports, consolidated revenue went from KRW 138.9 billion in 2022 to KRW 137.2 billion in 2023 (down 1.2%) and KRW 133.1 billion in 2024 (down 3.0%), before reaching KRW 140.9 billion in 2025 (up 5.8%), the largest year of the 2022–2025 period.

Operating results were an operating loss of KRW 592 million in 2022, an operating profit of KRW 365 million in 2023 (a swing to profit from the prior year), KRW 11.7 billion in 2024 (up 3,108.8%), and KRW 11 billion in 2025 (down 5.8%).

The operating margin was -0.4% in 2022, 0.3% in 2023, 8.8% in 2024 and 7.8% in 2025, so it peaked in 2024 and eased slightly in 2025.

The 2024 improvement came largely from costs: cost of sales fell by about KRW 6.9 billion from 2023, lowering the cost-of-sales ratio from 64.4% to 61.2%, while general R&D spending as a share of sales dropped from 5.2% to 2.1%.

Product sales fell sharply the same year, which left top-line growth stalled and explains the 2024 revenue decline.

Profit attributable to controlling shareholders was a loss of KRW 5.99 billion in 2022 and a loss of KRW 7.18 billion in 2023 (losses continued and widened), turned to a profit of KRW 8.72 billion in 2024, and was KRW 8.15 billion in 2025 (down 6.5%).

Net income including non-controlling interests is a different figure, at a loss of KRW 4.43 billion in 2022, a loss of KRW 5.54 billion in 2023, a profit of KRW 10.3 billion in 2024 and KRW 9.12 billion in 2025.

In the quarters, the third quarter of 2025 showed sales of KRW 37.8 billion and operating profit of KRW 4.99 billion, then the fourth quarter fell to sales of KRW 34.3 billion (down 9.1% from the prior quarter) and an operating loss of KRW 129 million (a swing to loss).

Sales then rose to KRW 35.5 billion in the first quarter of 2026 (up 3.5%) with operating profit of KRW 4.3 billion (a swing back to profit), to KRW 36.7 billion in the second quarter (up 3.3%) with operating profit of KRW 4 billion (down 7.0%), and to KRW 37 billion in the third quarter (up 0.8% quarter on quarter, down 2.1% year on year) with operating profit of KRW 3.27 billion (down 18.3% quarter on quarter and 34.4% year on year).

Profit attributable to controlling shareholders for the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, totals KRW 11.4 billion.

05

Industry analysis

The Korean prescription drug market is structured around generics and is heavily shaped by drug pricing policy. Yuyu Pharma puts its generic share at roughly 70%, so its revenue is relatively sensitive to price adjustments.

According to industry reports, the company is reviewing whether to pursue innovative pharmaceutical company certification, but it has not yet decided to file and is assessing whether it meets the requirements.

The gap against the criteria is clear: R&D spending was KRW 820 million in the first quarter of 2026, or 3% of sales, while the requirement for companies with annual sales above KRW 100 billion is 7%. Demographic aging is cited as a supportive backdrop for demand.

In animal medicines, the company is pursuing a direct entry strategy into the United States and is building companion animal products as a new growth engine. Against larger listed peers such as Yuhan and Hanmi Pharm, Yuyu Pharma is smaller by sales, which constrains how fast it can expand its own pipeline.

On the production side, it is pushing a smart factory transition with robotics to strengthen cost competitiveness. Its business model also differs from biotech-focused listed companies, combining generics, health functional foods and animal medicines.

06

Outlook

In its 2026 corporate value-up plan, the company said it would complete a treasury share cancellation in the first half and work to raise dividends. The same plan targets continued sales growth and firm profitability.

Yuyu Pharma has stated that it qualifies as a high-dividend company under the Restriction of Special Taxation Act, and its dividend payout ratio for 2025 was 26.2%.

On the business side, the companion animal business is being pushed in earnest in 2026, and a smart factory transition that introduces robots into production is under way to build cost competitiveness.

The YUNICAP multi-form capsule platform has been developed, and the company plans to use it in its own products and in contract manufacturing. Media reports also described an application to a prostate treatment.

The company said its standalone cumulative sales and operating profit for January through September 2026 grew by double digits, but consolidated quarterly operating profit fell for two straight quarters in the second and third quarters of 2026.

The next checkpoint is therefore whether the 2026 annual report shows fourth-quarter operating profit and margin reversing that trend. The company's stated goals of staying in profit and sustaining sales growth will be tested by those figures.

07

Valuation

PER
5.5×
PBR
0.5×
ROE
8.6%
EPS
₩667
BPS
₩7,967
Dividend per share
₩115

The starting point for valuation is to read earnings scale, net assets and the shareholder return structure together. Market capitalization sits below the equity attributable to controlling shareholders at the end of 2025, so the stock trades at a discount to book value in factual terms.

That comparison does not mean net assets fully capture the business value. Profit attributable to controlling shareholders totals KRW 11.4 billion over the last four quarters, while operating profit fell for two straight quarters in the second and third quarters of 2026, so the earnings trend is a key variable.

The company says it qualifies as a high-dividend company, and its 2025 dividend payout ratio was 26.2%. Multiples relative to past trading ranges move with the share price, so valuation should be read alongside whether profit recovers.

The operating margin eased from 8.8% in 2024 to 7.8% in 2025, and the margin trend in the third quarter of 2026 is the next reference point.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-18

08

Bull factors

Sales growth over three straight quarters

Sales have risen for three straight quarters since the fourth-quarter 2025 low, reaching KRW 37 billion in the third quarter of 2026. Annual 2025 sales of KRW 140.9 billion were the highest of the 2022–2025 period, a rebound from the decline in 2024.

Shareholder return plan and high-dividend status

In its corporate value-up plan disclosed on March 24, 2026, the company said it would complete a treasury share cancellation in the first half and work to raise dividends. It has stated that it qualifies as a high-dividend company, and its 2025 dividend payout ratio was 26.2%. Whether the cancellation and dividend increase are carried out can be confirmed in later disclosures.

Cost improvement and new business expansion

The cost-of-sales ratio fell from 64.4% in 2023 to 61.2% in 2024, and the operating margin reached 8.8% that year. The company is pursuing cost competitiveness through its smart factory transition and robotics.

Standalone operating profit for January through September 2026 was KRW 13.2 billion, up 53.1%, according to provisional figures announced on November 17, 2026.

09

Bear factors

Profit slowdown in the second half of 2026

Third-quarter 2026 operating profit fell from a year earlier, making the second-half profit slowdown evident. It has declined for two straight quarters since the first-quarter 2026 peak. Third-quarter sales were also down 2.1% year on year, so the top-line recovery has not translated into profit recovery.

Product concentration and pricing sensitivity

In the first quarter of 2026, the coated tablet and soft capsule groups together accounted for 64.7% of total sales. With generics at roughly 70% of the mix, drug price adjustments feed directly into results. The pharmaceutical share rose to 76.44% in the first quarter of 2026 from 69.74% in 2024.

A history of stalled top-line growth

Annual sales declined to KRW 137.2 billion in 2023 and KRW 133.1 billion in 2024. Reports attributed the stalled top line in 2024 to a sharp fall in product sales. The loss attributable to controlling shareholders widened to KRW 7.18 billion in 2023, and it fell 6.5% in 2025.

10

Risk factors

Drug pricing and policy risk

Generics make up roughly 70% of the mix and pharmaceuticals dominate revenue, so results are sensitive to price adjustments and policy changes.

Whether the company meets innovative pharmaceutical company certification requirements is tied to R&D spending, and first-quarter 2026 R&D was 3% of sales against a 7% benchmark.

Product concentration risk

In the first quarter of 2026, two product groups, the Tanamin-based coated tablets and the Neumaco-based soft capsules, made up 64.7% of total sales. A change in prescriptions or pricing for either would move quarterly sales materially. Whether companion animal and contract manufacturing businesses reduce this concentration is the item to track.

Quarterly profit volatility

The fourth quarter of 2025 swung to an operating loss of KRW 129 million, and the first quarter of 2026 returned to profit. Operating profit then declined in the second and third quarters of 2026.

The standalone cumulative figures announced on November 17, 2026 use a different basis from the consolidated quarterly results, so the two should not be combined.

11

What to watch next

  1. Late March 2027

    The 2026 annual report is due around this time, and it will be the first periodic report to confirm fourth-quarter 2026 results. The key items are annual operating profit and operating margin compared with KRW 11 billion and 7.8% in 2025.

  2. March 2027 (annual general meeting period)

    This is the dividend resolution for fiscal 2026, which will show whether the dividend increase pledged in the March 2026 value-up plan was carried out. The high-dividend status and payout ratio can be checked at the same time.

  3. Around May 15, 2027

    This is the filing deadline for the first-quarter 2027 report. Comparing it with first-quarter 2026 operating profit of KRW 4.3 billion will show whether the second-half 2026 decline is continuing.

  4. After December 2026 (timing not set)

    This is when a decision on applying for innovative pharmaceutical company certification would emerge. The item to track is whether R&D intensity moves closer to the 7% benchmark from its current level of about 3%.

  5. First half of 2027 (timing not set)

    This is the point to check whether the YUNICAP platform applied to a prostate treatment and contract manufacturing work show up in revenue. Companion animal sales contribution should be checked alongside.

12

Overall view

Yuyu Pharma recorded its largest year of the 2022–2025 period with 2025 sales of KRW 140.9 billion, and quarterly sales have risen for three straight quarters from the first quarter through the third quarter of 2026.

Over the same span, operating profit has fallen for two straight quarters since its first-quarter 2026 peak, and third-quarter 2026 operating profit of KRW 3.27 billion was down 34.4% from a year earlier. The fall in operating margin from 8.8% in 2024 to 7.8% in 2025 is also part of the picture.

The provisional standalone operating profit of KRW 13.2 billion for January through September 2026, announced on November 17, 2026, shows growth, but it is on a different basis from the consolidated quarterly results and should be read separately.

On the shareholder return side, the treasury share cancellation target, the dividend increase effort and the high-dividend status are supportive factors.

The weaker factors are price sensitivity from a generics-based structure, revenue concentrated in two product groups, and the profit slowdown that has continued since the second quarter of 2026.

The next checkpoints are the fourth-quarter operating profit in the 2026 annual report and the first-quarter 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. news.nate.com
  2. alphabiz.co.kr
  3. hankyung.com
  4. mydaily.co.kr
  5. weekly.hankooki.com
  6. asiatime.co.kr
  7. newspim.com
  8. comp.fnguide.com
  9. medigatenews.com
  10. businessplus.kr
  11. dailypharm.com
  12. m.news.nate.com
  13. m.news.nate.com
  14. kind.krx.co.kr
  15. needinfo.co.kr
  16. bloter.net
  17. thebionews.net
  18. fntimes.com

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis